Oral Squamous Cell Carcinoma Clinical Trial
— NEOPCOSCCOfficial title:
A Multi-Center, Randomized Phase III Study of Neoadjuvant Anti-PD-1 Immunotherapy Plus TP Chemotherapy Versus TP Chemotherapy or Up-Front Surgery in Resectable Locally Advanced Oral Squamous Cell Carcinoma
The purpose of this study is to investigate the survival benefit of neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy compared with TP chemotherapy or up-front surgery in resectable locally advanced oral squamous cell carcinoma.
Status | Recruiting |
Enrollment | 309 |
Est. completion date | October 1, 2026 |
Est. primary completion date | July 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Histologically documented oral squamous cell carcinoma (biopsy required). 2. Local advanced oral squamous cell carcinoma (clinical stage T1-2N1-2M0, T3-4aN0-2M0) with resection option for potential cure, as assessed by a faculty surgeon at Hospital of Stomatology, Wuhan University. 3. Distant metastasis is excluded by chest CT and emission computed tomograph. 4. Adequate organ function as follows: 1) Leukocyte count = 2,000/mm3; 2) Absolute neutrophil count = 1,000/mm3; 3) Platelet count = 100,000/mm3; 4) Hemoglobin = 90 g/L; 5) Serum albumin =30 g/L; 6) Total bilirubin = 1.5 × upper limit of normal (ULN); 7) AST (SGOT) and ALT (SGPT) < 2.5 × ULN; 8) ALP = 2.5 × ULN; 9) Prothrombin time-international normalized ratio = 1.5; 10) Serum creatinine = 1.5 × ULN; 11) INR/PT= 1.5; 12) TSH = ULN. 5. ECOG performance status 0-1. 6. Female patient tested HCG negative in serum or urine within 7 days prior to the start of investigational product. Both patient and partner must agree to use contraception prior to study entry and for the duration of study participation and for up to 120 days after the last dose of PD-1 blockade. 7. Patient understands the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form. Exclusion Criteria: 1. History of = 3 grade immune related adverse events (irAEs) or have not recovered to = 1 grade irAEs from previous treatment. 2. History of other treatments for cancer, including surgery, chemotherapy, radiotherapy or molecular targeted therapy within past 5 years. 3. Previous therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 or any other antibody targeting T cell co-regulatory pathways. 4. Active autoimmune disease or history of refractory autoimmune disease. 5. Active systemic infection requiring therapy. 6. Patients who are receiving psychotropic drug or alcohol/drug abuse. 7. Subjects with concurrent other active malignancies. 8. HIV or untreated active HBV or HCV infections, or vaccinated (HBV, flu, varicella, etc) within 4 weeks before recruitment. 9. Uncontrollable systemic diseases, including diabetes, hypertension, etc. 10. History of stroke or transient ischemic attack within past 6 months. 11. Distant metastases or inability to resect after physician evaluation. 12. Serious cardiovascular, respiratory, immune system critical disease or other conditions that the researchers thought might increase the subjects' risk. |
Country | Name | City | State |
---|---|---|---|
China | Xiangya Hospital of Central South University | Changsha | Hunan |
China | Peking university Shenzhen hospital | Shenzhen | Guangdong |
China | Hospital of Stomatology, Wuhan University | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Hospital of Stomatology, Wuhan University | Jiangsu HengRui Medicine Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in the Level of Circualting Exosomal PD-L1. | The level of circulating exosomal PD-L1 at serial time points pre- and on-treatment, as detected by enzyme-linked immunosorbent assay (ELISA). | 24 months. | |
Primary | Event-free Survival (EFS) Rate on Each Treatment Arm. | EFS is the time from the date of randomization to the date of first record of disease progression as defined by RECIST 1.1. | 24 months. | |
Secondary | Overall Survival (OS) on Each Treatment Arm. | OS is the time from randomization to death due to any cause. | 24 months. | |
Secondary | Radiographic Response. | Clinical response of tumors and lymph nodes to neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy, as evaluated by radiographic examinations and defined by RECIST 1.1.
Clinical response of tumors and lymph nodes to neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy, as evaluated by radiographic examinations and defined by RECIST 1.1. |
8 weeks. | |
Secondary | Pathologic Response. | Pathologic response of resected tumors and lymph nodes to neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy. Pathologic response is defined as sum of pathologic complete response and major pathologic response. Pathologic complete response is defined as the absence of viable residual tumor in resected specimen. The rate of major pathologic response, defined as <10% residual viable tumor cells in the resected specimen. | 8 weeks. | |
Secondary | Adverse Events (AEs). | Number of participants experiencing any sign, symptom, disease, or worsening of preexisting conditions temporally associated with the experimental interventions or irrespective of the experimental interventions. | 24 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04543266 -
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
|
||
Not yet recruiting |
NCT06438939 -
NBI for Early Diagnosis of OPMD/OSCC
|
N/A | |
Recruiting |
NCT05024383 -
Dissecting the Heterogeneity of Oral Cancer Pain
|
N/A | |
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
Recruiting |
NCT05069857 -
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
|
Phase 2 | |
Not yet recruiting |
NCT03619304 -
Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line
|
N/A | |
Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05893888 -
Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
Not yet recruiting |
NCT06130007 -
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
|
Phase 2 | |
Recruiting |
NCT02739204 -
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05708209 -
The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
|
||
Recruiting |
NCT05862168 -
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial
|
Phase 2 | |
Recruiting |
NCT05451303 -
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
|
||
Recruiting |
NCT05902455 -
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
|
||
Not yet recruiting |
NCT05803915 -
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
|
Phase 2 | |
Recruiting |
NCT05791149 -
Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity
|
N/A |